IR Banner

Press Releases

Date Title and Summary Additional Format
Mar 3, 2022
CEO Update: Celebrating Rare Disease Day - A Conversation with MAGIC Foundation Co-Founder
Rare Disease Day, occurring each year on the last day of February, is a very special day for the rare disease community and for those of us privileged to work with organizations supporting those affected by rare disorders. At Lumos Pharma, we are currently focused on pediatric growth hormone
Feb 23, 2022
Lumos Pharma to Report Full Year 2021 Financial Results and Host Conference Call on March 10, 2022
AUSTIN, Texas , Feb. 23, 2022 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, today announced it will report its full year 2021 financial results after market close on Thursday, March 10, 2022 .
Jan 5, 2022
Lumos Pharma to Present at the H.C. Wainwright BIOCONNECT Virtual Conference
AUSTIN, Texas , Jan. 05, 2022 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc.  (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, announced that the Company will present at the H.C. Wainwright Virtual BIOCONNECT Conference being held January 10-13, 2022 .
Nov 10, 2021
Lumos Pharma to Participate in Upcoming Investor Conferences
AUSTIN, Texas , Nov. 10, 2021 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc.  (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, announced that the Company will participate in the following upcoming investor conferences:   Event:   Stifel 2021 Virtual
Nov 3, 2021
Lumos Pharma Reports Third Quarter 2021 Financial Results and Provides Clinical Updates
Majority of OraGrowtH210 Trial sites are open with recent and imminent openings representing historically high enrollment sites Six-month primary outcome data readout from OraGrowtH210 expected 2H 2023 AUSTIN, Texas , Nov. 03, 2021 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc.
Oct 21, 2021
Lumos Pharma to Report Third Quarter 2021 Financial Results and Host Conference Call on November 3, 2021
AUSTIN, Texas , Oct. 21, 2021 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, today announced it will report its third quarter 2021 financial results after market close on Wednesday, November 3, 2021 .
Sep 2, 2021
Lumos Pharma to Participate in September Investor Conferences
AUSTIN, Texas , Sept. 02, 2021 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc.  (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, announced that the Company will participate in the H.C. Wainwright 23 rd Annual Global Investment Conference and the Cantor
Aug 5, 2021
Lumos Pharma Reports Second Quarter 2021 Financial Results and Provides Clinical and Corporate Updates
• Lumos Pharma strengthens leadership team with promotion of John McKew , PhD to President, and addition of David B. Karpf , MD as Chief Medical Officer and Mark Bach , MD, PhD to Advisory Board • Screening and enrollment of OraGrowtH210 and OraGrowtH212 Trials progress AUSTIN, Texas , Aug.
Aug 3, 2021
Lumos Pharma Announces Industry Veteran, David B. Karpf, MD, has Joined the Company as Chief Medical Officer
AUSTIN, Texas , Aug. 03, 2021 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, has announced that experienced endocrinologist and pharma executive, David B. Karpf , MD, joined the Company August 3, 2021 as
Aug 2, 2021
Lumos Pharma Announces the Promotion of COO and Chief Scientific Officer, John McKew, PhD, to President
AUSTIN, Texas , Aug. 02, 2021 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, has announced that current Chief Operating Officer and Chief Scientific Officer, John McKew , PhD, was promoted to President of
Displaying 21 - 30 of 67